Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focus |
immunology
cardiovascular diseases gastrointestinal diseases |
| gptkbp:founded |
1997
|
| gptkbp:founder |
gptkb:Jack_Lief
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Belviq
gptkb:Etrasimod gptkb:Ralinepag |
| gptkbp:numberOfEmployees |
~200 (prior to acquisition)
|
| gptkbp:status |
defunct (as of 2022, after acquisition)
|
| gptkbp:tradedOn |
gptkb:Nasdaq:_ARNA
|
| gptkbp:website |
https://www.arenapharm.com/
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:bfsLayer |
6
|
| http://www.w3.org/2000/01/rdf-schema#label |
Arena Pharmaceuticals
|